Q-omics provides the consensus-scored NT5C3A profile across patient tissues and cancer cell-line models. NT5C3A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NT5C3A is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, NT5C3A protein abundance shows 30,254 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LIHC, KIRC, and HNSC as cancer lineages where NT5C3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NT5C3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NT5C3A survival associations across molecular data types. NT5C3A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NT5C3A RNA expression–survival associations across cancer types. High NT5C3A expression shows unfavorable associations in LIHC, ACC, LGG and LUAD, but favorable associations in THCA and CHOL. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for NT5C3A RNA expression.
This table summarizes NT5C3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NT5C3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NT5C3A shows higher tumor expression in KIRC, KIRP, BLCA, LIHC, STAD and LUAD. The KIRC box plot shows higher NT5C3A RNA expression in tumor versus normal tissue (log2 FC = +1.149, t-test p < 0.001).
This table shows molecular features associated with NT5C3A in patient tissues and cancer cell lines. In patient samples, NT5C3A shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, NT5C3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and PANCREAS.
